PURCHASE, NY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, today published its fourth annual Corporate Social Responsibility (CSR) report. The latest report highlights the organization’s growing positive impact on communities around the globe—from expanding access to equitable care and advancing health equity, to further reducing packaging materials to support sustainability goals. It also follows a landmark year for the company, which surpassed 90 million members as of September 30, 2023.
“Our continued momentum and unsurpassed scale helped us make an even greater impact this year,” said Jason Gorevic, chief executive officer of Teladoc Health. “Our CSR work remains integral to our mission to empower all people everywhere to live their healthiest lives.”
Key highlights from this year’s report include:
“From pioneering human-centered design and responsible AI, to investing in our supply chain and sustainability goals, we continue to embrace the opportunity and responsibility to care for our communities, our colleagues and our planet,” said Stephany Verstraete, chief marketing and engagement officer of Teladoc Health. “Our mission-focused work has never been more important.”
To view Teladoc Health’s full report and learn more about the company’s CSR efforts, click here.
About Teladoc Health
Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.
Carolyn Edwards, (321) 795-1952, This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$6.90 |
Daily Change: | -0.24 -3.36 |
Daily Volume: | 4,380,307 |
Market Cap: | US$1.190B |
March 12, 2025 March 11, 2025 March 04, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load